Wockhardt Q2 Revenue Rises 24% Amid Zaynich Launch Expenses and Miqnaf Expansion
Wockhardt reported a 24% year-on-year revenue increase to Rs 969 crore in Q2 FY27, driven by strong demand for its biotechnology products and expanded marketing of its novel antibiotic Miqnaf in India after the removal of a supply condition. However, net profit declined 11% to Rs 73 crore due to Rs 36 crore in pre-launch expenses for Zaynich, a new antibiotic approved by the US FDA for complicated urinary tract infections. The company plans further filings for Miqnaf and continues regulatory progress for Zaynich in Europe.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (62/100). Lens Score 46/100.
Outlets measured: moneycontrol, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 2 Nov, 12:03 pm. Other outlets followed.